Genmab’s interim report for the first half of 2025 highlights the advancement of epcoritamab in therapy lines, progress of Rina-S in endometrial cancer, and revenue increase of 19% to $1,640 million compared to 2024. The company aims to bring innovative therapies to more patients and accelerate late-stage pipeline development.

Financially, Genmab saw revenue of $1,640 million in the first half of 2025, driven by higher DARZALEX and Kesimpta royalties. Operating profit was $548 million, and net financial items resulted in income of $119 million. Genmab is updating its revenue and operating profit guidance for 2025 due to higher royalty revenues from DARZALEX.

Genmab’s first half of 2025 report also highlights changes in functional and presentation currency to USD effective January 1, 2025. The company will hold a conference call to discuss the results on August 7. Forward-looking statements in the report outline key risk factors affecting Genmab’s performance and strategies for future growth and success.

For more detailed information, the full Interim Report for the First Half of 2025 is available for download on Genmab’s investor relations website. Genmab is focused on advancing its innovative therapies, maximizing revenue potential, and expanding its product pipeline to bring more treatments to patients in need.

Read more at GlobeNewswire: Genmab Announces Financial Results for the First Half of